Pfizergan Offers Warm Embrace For Pfizer’s Internal And Allergan’s External R&D
Pfizer R&D chief Mikael Dolsten and his counterpart at Allergan, David Nicholson, oversee very different research organizations, but in interviews at the J.P. Morgan Healthcare Conference the two heads of R&D insisted the chasm between their research models is not so vast.
You may also be interested in...
A regulatory filing for Vyjuvek in the US is targeted for the first half of 2022 following the positive results of a Phase III trial, positioning Krystal for its first commercial launch.
The company has ramped up a broad R&D program for the FcRn inhibitor in 11 autoantibody-driven disease areas.
Deal Snapshot: Neurocrine expanded its pipeline with rights to subtype-selective muscarinic M4, M1 and dual M1/M4 receptor agonists discovered by Sosei.